

LifeSci Biotechnology Products Index
LifeSci Biotechnology Clinical Trials Index
Index Semi-Annual Reconstitution (Preliminary)
June 9, 2020

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Tuesday, June 16, 2020. All positions will be equally weighted, with weights determined as of the closing prices on Friday, June 12, 2020. The preliminary changes, subject to modification, are summarized below.

LifeSci Biotechnology Clinical Trials Index

Additions (45 stocks):

- ADAP, APLT, APRE, ARQT, BCEL, BDTX, BNTX, BTAI, CALA, CGEN, CRNX, CUE, DVAX, EDIT, FREQ, HARP, IGMS, KNSA, KZR, MEIP, MIRM, MRNS, MRSN, MTEM, NGM, NTLA, NVAX, OVID, OYST, PHAT, PRTA, PRVL, PTGX, RAPT, RCUS, RLMD, RUBY, RVMD, SELB, SNDX, SYRS, VIE, VIR, VSTM, XENE

Deletions (8 stocks):

- AUTL, GLYC, PGNX, UBX (no longer fit index criteria)
- BPMC, EPZM, ESPR, IMMU (being moved to Products Index based on FDA approval)

LifeSci Biotechnology Products Index

Additions (4 stocks):

- BPMC, EPZM, ESPR, IMMU (being moved from Clinical Trials Index)

Deletions (3 stock):

- LXRX, PTLA, STML

The LifeSci Biotechnology Indexes are equal-weighted indexes that track the performance of U.S.-listed biotechnology stocks in two distinct stages in the lifecycle of biotechnology companies – Clinical Trials stage and Product stage. The indexes are calculated with a base value of 1,000 as of June 30, 2004 and have an official inception date of November 3, 2014.

For more information, visit www.lifesciindex.com